Rationale for Correct Answer

The correct answer is: KRAS G12C only

The FDA-approved agents adagrasib and sotorasib are approved for treating advanced and metastatic NSCLC in patients whose tumors carry KRAS G12C mutations only.1 These agents can only react with cysteine residues, so they have no activity against NSCLC tumors carrying KRAS G12V, G12A, or G12D mutations.2

1. U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications. Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
2. Liu J et al. Cancer Gene Ther. 2022;29:875-878.